Timing of rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis
Author:
Affiliation:
1. Department of Medicine (DAME), Rheumatology Clinic ASUFC, University of Udine, Udine, Italy
Publisher
Oxford University Press (OUP)
Subject
Pharmacology (medical),Rheumatology
Link
http://academic.oup.com/rheumatology/advance-article-pdf/doi/10.1093/rheumatology/keab175/36651324/keab175.pdf
Reference8 articles.
1. Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature;Tepasse;Br J Haematol,2020
2. The impact of COVID-19 pandemic on patients with ANCA associated vasculitis;Kant;J Nephrol,2020
3. Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia;Guilpain;Ann Rheum Dis,2021
4. Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab;Schulze-Koops;Ann Rheum Dis,2020
5. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry;Strangfeld;Ann Rheum Dis,2021
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. COVID-19 in a patient with granulomatosis with polyangiitis: Management tactics;Rheumatology Science and Practice;2023-03-02
2. Safety of Biologic-DMARDs in Rheumatic Musculoskeletal Disorders: A Population-Based Study over the First Two Waves of COVID-19 Outbreak;Viruses;2022-07-01
3. Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through circulating immunoglobulins, neutrophils or B cells;Rheumatology;2022-06-10
4. Monoclonal anti-CD20 antibodies in lymphomas therapy during the COVID-19 pandemic: pro and contra;Oncohematology;2022-04-13
5. Impact of the COVID-19 pandemic on uveitis patient care;British Journal of Ophthalmology;2022-01-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3